Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126706871 | 12670687 | 1 | I | 20160506 | 20160822 | 20160822 | PER | US-LUPIN PHARMACEUTICALS INC.-2016-02025 | LUPIN | BIO L, BRILLANTES M. INCIDENCE OF VANCOMYCIN-INDUCED RED MAN SYNDROME IN PEDIATRIC PATIENTS. INFECTIOUS DISEASES IN CLINICAL PRACTICE. 2016 MAR;24(2):106-108. | 14.00 | YR | F | Y | 0.00000 | 20160822 | COUNTRY NOT SPECIFIED | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126706871 | 12670687 | 1 | PS | Vancomycin | VANCOMYCIN | 1 | Intravenous (not otherwise specified) | 620-MG (15 MG/KG PER DOSE) INFUSION FOR 1 HOUR | UNKNOWN | 90439 | Q6H | ||||||||
| 126706871 | 12670687 | 2 | SS | Vancomycin | VANCOMYCIN | 1 | Intravenous (not otherwise specified) | 7.5 MG/KG PER HOUR FOR 2 HOURS | UNKNOWN | 90439 | Q6H |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126706871 | 12670687 | 1 | Cellulitis orbital |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126706871 | 12670687 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126706871 | 12670687 | Red man syndrome |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |